GSK news: bullish momentum holds above key moving averages despite short-term pullback

Traders Union
All News
Financial News
GSK slides 1.28% today to GBX 1,776

Highlights

GSK repurchased 170,000 ordinary shares on November 14, 2025, as part of its ongoing share buyback program, demonstrating active capital management.
Post-transaction, GSK holds 256,464,844 shares in treasury out of a total of 4,058,966,266 shares in issue.
GSK Egypt reported a significant drop in consolidated net profits year-to-date and posted net losses in Q3 2025 compared to the prior year.

Active buybacks and profit drop in Egypt as capital allocation shifts

GSK executed a repurchase of 170,000 ordinary shares on November 14, 2025, as part of its ongoing share buyback program, highlighting active capital management efforts. Following this transaction, the company now holds 256,464,844 shares in treasury out of a total of 4,058,966,266 shares in issue. In regional news, GSK Egypt reported a significant drop in consolidated net profits for the first nine months and posted net losses in Q3 2025 compared to the prior year.

Support zone holds as bullish momentum clashes with short-term exhaustion

The nearest dynamic support is indicated by the Ichimoku Kijun at GBX 1,713.25, while the MA-50 zone now acts as stronger support; resistance can be expected near recent highs or round levels above GBX 1,800. Momentum signals on the daily chart remain broadly positive, as reflected in a strong MACD buy signal and an ADX of 28.18, indicating the trend is well established. RSI and CCI are in bullish territory, but Stoch RSI shows an oversold reading, and the BBP indicator points to overbought conditions, hinting at short-term buyer exhaustion. Today saw a modest gap down (previous close: GBX 1,799.50; open: GBX 1,797.50) and the price has slipped 1.28% to sit near the lower end of the daily range, indicating moderate volatility and persistent selling pressure after the open. There is a clear divergence between longer-term momentum (bullish) and mixed short-term oscillator readings, which suggests a need for caution if downside pressure continues intraday.

High probability of upside as technicals overwhelm downside risk

For the next five trading days, the expected price range is GBX 1,770 to GBX 1,790, adjusted for recent volatility and the current price position. Based on the strong alignment of bullish signals from the weekly RSI, ADX, MACD, and MA-50, there is a very high probability (more than 80%) of further price increases, making downside moves less likely in the short term. The baseline scenario foresees the price holding within a sideways band near GBX 1,780, while a bullish scenario would see a break above GBX 1,790–GBX 1,800 resistance, and a bearish scenario would come into play if the price falls below GBX 1,770 and loses support at the Kijun level.

Anton Kharitonov, technical and fundamental analyst at Traders Union, notes GSK remains technically strong above its key moving averages, yet short-term oscillators warn of buyer fatigue. He sees robust momentum signals, but recent selling pressure near GBX 1,780 and disappointing results from GSK Egypt require a cautious approach. The analyst believes price action will likely stay rangebound unless support at GBX 1,770 fails. "Base case remains neutral as long as GBX 1,770 holds — if that breaks, expect further downside in the short term."

Previously it was noted that GSK continued its share buyback activity and formed a new partnership to advance tuberculosis treatment. The technical analysis discussed overbought momentum alongside robust trend based on market signals.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.